TY - JOUR AU - Parnetti, Lucilla AU - Chipi, Elena AU - Salvadori, Nicola AU - D’Andrea, Katia AU - Eusebi, Paolo PY - 2019 DA - 2019/01/15 TI - Prevalence and risk of progression of preclinical Alzheimer’s disease stages: a systematic review and meta-analysis JO - Alzheimer's Research & Therapy SP - 7 VL - 11 IS - 1 AB - Alzheimer’s disease (AD) pathology begins several years before the clinical onset. The long preclinical phase is composed of three stages according to the 2011National Institute on Aging and Alzheimer’s Association (NIA-AA) criteria, followed by mild cognitive impairment (MCI), a featured clinical entity defined as “due to AD”, or “prodromal AD”, when pathophysiological biomarkers (i.e., cerebrospinal fluid or positron emission tomography with amyloid tracer) are positive. In the clinical setting, there is a clear need to detect the earliest symptoms not yet fulfilling MCI criteria, in order to proceed to biomarker assessment for diagnostic definition, thus offering treatment with disease-modifying drugs to patients as early as possible. According to the available evidence, we thus estimated the prevalence and risk of progression at each preclinical AD stage, with special interest in Stage 3. SN - 1758-9193 UR - https://doi.org/10.1186/s13195-018-0459-7 DO - 10.1186/s13195-018-0459-7 ID - Parnetti2019 ER -